卖什么
Robotic human cell manufacturing
商业模式拆解
买家：谁掌握预算？
Cell and regenerative medicine therapy developers (e.g. Aspen Neuroscience, Novadip, Rinri, StemSight) outsourcing manufacturing.
触发点：什么让他们现在购买？
Therapies work in clinic but manual production does not scale or is too costly for Phase 3 and commercialization.
工作流：什么输入变成什么输出？
Request info, scoping study and "Proof of Value" on the iDEM platform, then scale production in Mytos automated cleanroom site (UK).
经济账：省了什么，怎么收费？
Automated CDMO: claims 4x faster scaling, 10x batches per cleanroom, 40% lower cost per batch, 10x fewer FTE hours.
渠道：怎么接触到客户？
Direct enterprise sales with partnerships and collaborations (Request Info form).
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2018 夏季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.